Phaseline

Targets › CNGA3

CNGA3 (Cyclic nucleotide-gated channel alpha-3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout Jun 2027.

Pore-forming subunit of the cone cyclic nucleotide-gated channel. Mediates cone photoresponses at bright light converting transient changes in intracellular cGMP levels into electrical signals. (UniProt, Q16281)

Open in Phaseline: the race on CNGA3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
STZ eyetrialrAAV.hCNGA3
Recombinant adeno-associated virus vector delivering human CNGA3 gene for gene therapy of
CNGA3Phase 1AchromatopsiaJun 2027

Conditions

Achromatopsia (1)

Modalities

small molecule (1)

Companies

STZ eyetrial (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.